Besifloxacin is a modern fluoroquinolone antibiotic primarily used to treat bacterial eye infections such as bacterial conjunctivitis. It works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication and cell division, effectively stopping bacterial growth. Besifloxacin is formulated as an ophthalmic suspension, allowing direct topical application to the eye with minimal systemic absorption. Its broad-spectrum activity covers both gram-positive and gram-negative bacteria, including strains resistant to older fluoroquinolones. The drug was developed in the early 2000s to address limitations of previous fluoroquinolones, especially for ocular use. It was designed to maximize efficacy and safety while reducing systemic side effects. Clinical studies demonstrated its rapid bactericidal activity, making it highly effective for short-course treatments. Besifloxacin received FDA approval in 2009 for the treatment of bacterial conjunctivitis, marking its official entry into ophthalmic therapeutics. Since then, it has become a preferred option in topical ocular antibiotic therapy due to its potency and minimal resistance profile. Its development reflects the advancement of targeted, site-specific antibiotics, offering effective local therapy without significant systemic exposure. Overall, besifloxacin represents a significant innovation in ophthalmic anti-infective therapy, combining modern fluoroquinolone chemistry with practical clinical application.
